News

Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to Qiagen’s wholly owned subsidiary DxS, presently Qiagen Manchester. Qiagen said

Dactinomycin has received approval from the FDA earlier this year. It is an equivalent of Lundbeck’s Cosmegen. Each single dose vial contains 0.5mg (500mcg) of dactinomycin and 20mg

Addicere Therapeutics, a wholly-owned subsidiary of Alexza, has been launched by the company to develop all applications of the Staccato technology for the pharmaceutical uses of nicotine. Thomas

Taliglucerase alfa is an enzyme replacement therapy that is expected to work by replacing the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it

The study was conducted to assess the in-vitro potency of SPET-085, an inhibitor of the 5alpha-reductase isoenzyme type II, in a cell-free test system. SPE has been used

Cogenzia is Innocoll’s topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers. Patients with a moderate or severe diabetic foot infection will be treated in

DuoCap is a single oral dosage unit that comprises a capsule-in-a-capsule and offers therapeutic applications. Encap claimed that the patented Duocap technology can provide protection for clients interested

Bristol-Myers informed that the lot numbers which are included in the recall are Physician Sample Blister Packs: Lot no 9A48931A, 9A48931B, 9A48931C, expiration January 2012; HUD Blister Pack:

ADX71943 is a selective positive allosteric modulator of gamma-aminobutyric acid subtype B (GABA-B) receptors. GABA-B receptors mediate the slow, prolonged physiological effects of the inhibitory neurotransmitter GABA and